Today the European Commission approved the label expansion of the first of our four #CysticFibrosis (CF) medicines. This marks an important step towards our goal of treating all people with CF.

We’re pleased to announce significant progress across our pain program. Learn more: news.vrtx.com/news-releases/…

Our investigational treatment for APOL1-mediated kidney disease (AMKD) will advance into the Phase 3 portion of our Phase 2/3 pivotal trial. Learn more: vrtx.com/?utm_source=tw…

Moving to the clinic: U.S. FDA clears our Investigational New Drug application for the potential treatment of autosomal dominant polycystic kidney disease (ADPKD). Learn more: vrtx.com/?utm_source=tw…

At Vertex, we’re inspired by the patients and communities we seek to serve. We’re proud to light up our #Boston building green on #WorldKidneyDay to raise awareness of and show our support for those living with APOL1-mediated #KidneyDisease (AMKD). #NationalKidneyMonth

On #RareDisease Day , our Boston office will be lit in pink, purple, blue and green to represent the 300 million people living with a #RareDisease . Join us in honoring this community and spreading awareness. #ShowYourStripes #ShareYourColours

The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for the label expansion of the first of our four #CysticFibrosis (CF) medicines. This marks an important step towards our goal of treating all people with CF.

#Breaking The European Commission (EC) approves our treatment for #SickleCellDisease and #BetaThalassemia for the European Union. Learn more: vrtx.com/?utm_source=tw…

Today the Australian Therapeutic Goods Administration (TGA) approved the indication expansion of our fourth #CysticFibrosis (CF) medicine. This marks an important step towards our goal of treating all people with CF.

Vertex Reports Fourth Quarter 2023 Financial Results.
news.vrtx.com/news-releases/…

We are pleased to announce positive Phase 3 results from our investigational triple combination therapy for the treatment of certain mutations of cystic fibrosis. Learn more: news.vrtx.com/news-releases/…

Today we’re excited to announce positive results from the Phase 3 studies of our investigational treatment for moderate-to-severe acute pain. Learn more: news.vrtx.com/news-releases/…

#Breaking The U.S. FDA approves our treatment for #BetaThalassemia . We are thrilled to see this approval provide a new option to eligible patients who have been waiting. Learn more: news.vrtx.com/news-releases/…

The Saudi Food and Drug Authority (SFDA) approves our treatment for #SickleCellDisease and #BetaThalassemia in the Kingdom of Saudi Arabia. Learn more: vrtx.com/?utm_source=co…

The EMA’s Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for our #SickleCellDisease and #BetaThalassemia treatment; an important step in bringing this treatment to patients in the European Union. Learn more: vrtx.com

Today we’re excited to share the positive results from the Phase 2 study of our investigational pain treatment for people with painful diabetic peripheral neuropathy. Learn more here: news.vrtx.com/news-releases/…

Our teams and investigators shared new clinical data on our research in sickle cell disease and beta thalassemia at the @ASH_Hematology 2023 Annual Meeting. Learn more: news.vrtx.com/news-releases/…

#Breaking : The U.S. FDA approves our treatment for #SickleCellDisease . We are excited to make this treatment available to patients. Learn more: news.vrtx.com/news-releases/…

We’re pleased to share the European Medicines Agency has validated the regulatory submission of our fourth cystic fibrosis medicine for an expanded population with certain rare mutations.

Today the European Commission approved the label expansion of our fourth #CysticFibrosis (CF) medicine. This marks an important step towards our goal of treating all people with CF.